Evidence map›Paper›PMID 40130208›Full record

ArticleInternational journal of cardiology. Heart & vasculature2025

A systematic review and meta-analysis of the hemodynamics and outcomes of the Myval balloon-expandable valve in patients with severe aortic stenosis and with aortic regurgitation.

Elfatih A Hasabo, Amira A Aboali, Lina Hemmeda, Ammar Elgadi, Salma S Alrawa, Alaa S Ahmed, Malaz M Abdalmotalib, Abdullatif Yasir H Eissa, Mohammed Mahmmoud Fadelallah Eljack, Sherif Sultan and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of cardiology. Heart & vasculature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Elfatih A HasaboRoyal College of Surgeons in Ireland (RCSI) University of Medicine and Health Sciences, Dublin, Ireland.
Amira A AboaliDamanhour Teaching Hospital, General Organization for Teaching Hospitals and Institutes, Damanhour, Egypt.
Lina HemmedaFaculty of Medicine, University of Khartoum, Khartoum, Sudan.
Ammar ElgadiFaculty of Medicine, University of Khartoum, Khartoum, Sudan.
Salma S AlrawaFaculty of Medicine, University of Khartoum, Khartoum, Sudan.
Alaa S AhmedFaculty of Medicine, University of Khartoum, Khartoum, Sudan.
Malaz M AbdalmotalibFaculty of Medicine, University of Khartoum, Khartoum, Sudan.
Abdullatif Yasir H EissaFaculty of Medicine, University of Khartoum, Khartoum, Sudan.
Mohammed Mahmmoud Fadelallah EljackFaculty of Medicine, University of Bakht Alruda, Al Dwuaym, Sudan.
Sherif SultanDepartment of Vascular and Endovascular Surgery, Western Vascular Institute, University College Hospital, Galway, Ireland.
Osama SolimanRoyal College of Surgeons in Ireland (RCSI) University of Medicine and Health Sciences, Dublin, Ireland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Transcatheter aortic valve implantation (TAVI) has been growing rapidly. We aim to evaluate the performance and outcomes of the Myval transcatheter heart valve (THV) in patients with severe aortic stenosis and its use in quantitative videodensimetry, transcatheter valve-in-valve (ViV), and non-calcified aortic regurgitation (NCAR). Methods: A systematic search was done in PubMed, Scopus, Web of Science, Embase, and Cochrane from inception to October 2024. We used the relevant keywords to include studies that reported the outcomes of patients with severe aortic stenosis who underwent TAVI using the Myval THV and off-label usage in transcatheter ViV and NCAR. Data analysis was done using R software. Results: A total of 29 studies were included in this study. The results of the mean aortic gradient at discharge, 30-day, one-year, and 2-year were 9.25 mmHg (95 % CI [8.20, 10.29]), 8.46 (95 % CI [7.57, 9.34]). 10.63 (95 % CI [9.12, 12.14]), and 7.2 (95 % CI [6.78, 7.63]), respectively. Additionally, the pooled percentages of patients with ≥ moderate aortic regurgitation were found in 1 % (95 % CI [1,2]) at discharge, 3 % (95 % CI [2,4]) at 30-day, 4 % (95 % CI [2,7]) at one-year follow-up and 5 % (95 % CI [3,8]) at 2-year. Furthermore, usage of the Myval THV in transcatheter ViV and NCAR led to a reduction in mean aortic gradient and incidence of aortic regurgitation, respectively. Conclusion: The Myval THV showed good safety and efficacy outcomes in short- and long-term follow-ups following the TAVI. Also, it showed promising results during transcatheter ViV and NCAR.

Indexed as

Aortic stenosisMyvalNon-calcified aortic regurgitationTranscatheter aortic valve implantationTranscatheter valve-in-valve

Identifiers

PMID40130208
PMCPMC11930208

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.